News and Trends 4 Oct 2019
ADC Therapeutics Cancels Nasdaq IPO Amidst Market Growth Fears
The Swiss biotech ADC Therapeutics has withdrawn its application for a €182M ($200M) Nasdaq IPO, citing adverse market conditions caused by global manufacturing slowdowns. ADC Therapeutics declined to comment on the specific market situation. Its withdrawal is likely due to slumps in European and US stock markets seen earlier this week caused by drops in […]